StockData
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. (NAUT) stock

NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 6/30
$2.36+0.26 (+12.38%)

Close on Nov 17, 2026Market cap $300.60MP/E –Yield –

Nautilus Biotechnology r&d expenses

Research and development expenses are spending on new products and technology.

Nautilus Biotechnology's R&D Expenses for the twelve months ending Sep 30, 2026 was $39.07M, down 11.9% year over year. For fiscal 2025 it was $41.11M, down 18.6% from the year before. The highest annual figure on record is $50.48M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$41.11M-18.6%
FY2024Dec 31, 2024$50.48M+6.8%
FY2023Dec 31, 2023$47.25M+25.4%
FY2022Dec 31, 2022$37.67M+28.3%
FY2021Dec 31, 2021$29.35M+136.1%
FY2020Dec 31, 2020$12.43M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$10.18M+5.9%
Q2 FY2026Jun 30, 2026$9.61M-7.5%
Q1 FY2026Mar 31, 2026$9.71M-15.9%
Q4 FY2025Dec 31, 2025$9.58M-25.3%
Q3 FY2025Sep 30, 2025$9.61M-21.8%
Q2 FY2025Jun 30, 2025$10.39M-16.4%
Q1 FY2025Mar 31, 2025$11.54M-10.8%
Q4 FY2024Dec 31, 2024$12.82M+2.9%
Q3 FY2024Sep 30, 2024$12.29M+2.4%
Q2 FY2024Jun 30, 2024$12.44M+4.4%
Q1 FY2024Mar 31, 2024$12.93M+18.9%
Q4 FY2023Dec 31, 2023$12.47M+30.0%
Q3 FY2023Sep 30, 2023$12.00M+25.3%
Q2 FY2023Jun 30, 2023$11.91M+34.5%
Q1 FY2023Mar 31, 2023$10.88M+12.6%
Q4 FY2022Dec 31, 2022$9.59M-3.1%
Q3 FY2022Sep 30, 2022$9.57M+16.1%
Q2 FY2022Jun 30, 2022$8.86M+38.8%
Q1 FY2022Mar 31, 2022$9.66M+99.8%
Q4 FY2021Dec 31, 2021$9.89M+154.1%
Q3 FY2021Sep 30, 2021$8.24M+148.5%
Q2 FY2021Jun 30, 2021$6.38M+131.9%
Q1 FY2021Mar 31, 2021$4.84M–
Q4 FY2020Dec 31, 2020$3.89M–
Q3 FY2020Sep 30, 2020$3.32M–
Q2 FY2020Jun 30, 2020$2.75M–

More Nautilus Biotechnology figures

See a number that looks wrong?